Literature DB >> 2859048

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.

R V Lewis, M S Lennard, P R Jackson, G T Tucker, L E Ramsay, H F Woods.   

Abstract

The pharmacokinetics and pharmacodynamics of atenolol and timolol were studied in six extensive and four poor metabolisers of debrisoquine. There was a significant correlation between the debrisoquine to 4-hydroxydebrisoquine ratio and the area under the plasma concentration time curve (AUC) for timolol (rs = 0.75, P less than 0.02). The mean of the AUC values for timolol was significantly greater in the poor metabolisers than in the extensive metabolisers (P less than 0.05). There was a significant correlation between the debrisoquine to 4-hydroxydebrisoquine ratio and beta-adrenoceptor blockade 24 h after dosing with timolol (rs = 0.66, P less than 0.05). The mean degree of beta-adrenoceptor blockade was significantly greater in the poor metabolisers than in the extensive metabolisers 24 h after dosing with timolol (P less than 0.01). There was no relation between the debrisoquine to 4-hydroxydebrisoquine ratio and the pharmacokinetics or pharmacodynamics of atenolol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859048      PMCID: PMC1463731          DOI: 10.1111/j.1365-2125.1985.tb02651.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Physiological disposition and metabolism of timolol in man and laboratory animals.

Authors:  D J Tocco; A E Duncan; F A Delauna; H B Hucker; V F Gruber; W J Vandenheuvel
Journal:  Drug Metab Dispos       Date:  1975 Sep-Oct       Impact factor: 3.922

3.  High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.

Authors:  G Alvan; C von Bahr; P Seidemann; F Sjöqvist
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

4.  Relationships among timolol doses, plasma concentrations and beta-adrenoceptor blocking activity.

Authors:  R K Ferguson; P H Vlasses; J R Koplin; G I Holmes; P Huber; J Demetriades; W B Abrams
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

5.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

6.  Oxidation phenotype--a major determinant of metoprolol metabolism and response.

Authors:  M S Lennard; J H Silas; S Freestone; L E Ramsay; G T Tucker; H F Woods
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245

7.  Atenolol determination by high-performance liquid chromatography and fluorescence detection.

Authors:  Y G Yee; P Rubin; T F Blaschke
Journal:  J Chromatogr       Date:  1979-04-01

8.  Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine.

Authors:  I Kitchen; J Tremblay; J André; L G Dring; J R Idle; R L Smith; R T Williams
Journal:  Xenobiotica       Date:  1979-07       Impact factor: 1.908

9.  Urinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activities.

Authors:  B K Wasson; J Scheigetz; C S Rooney; R A Hall; N N Share; W J VandenHeuvel; B H Arison; O D Hensens; R L Ellsworth; D J Tocco
Journal:  J Med Chem       Date:  1980-11       Impact factor: 7.446

10.  Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.

Authors:  S Freestone; J H Silas; M S Lennard; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

View more
  19 in total

1.  Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.

Authors:  R V Lewis; L E Ramsay; P R Jackson; W W Yeo; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 2.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  Prevalence of debrisoquine oxidation phenotypes in glaucoma patients.

Authors:  L Salminen; R Lindberg; H R Toivari; R Huupponen; T Kaila; E Iisalo
Journal:  Int Ophthalmol       Date:  1989-01       Impact factor: 2.031

4.  Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.

Authors:  M S Lennard; J C McGourty; J H Silas
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

5.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Timolol metabolism and debrisoquine oxidation polymorphism: a population study.

Authors:  M S Lennard; R V Lewis; L A Brawn; G T Tucker; L E Ramsay; P R Jackson; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 7.  Adverse reactions and interactions with beta-adrenoceptor blocking drugs.

Authors:  R V Lewis; D G McDevitt
Journal:  Med Toxicol       Date:  1986 Sep-Oct

Review 8.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 9.  Systemic reactions to ophthalmic drug preparations.

Authors:  F T Fraunfelder; S M Meyer
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

Review 10.  Beta-blocker therapy and the risk of anaphylaxis.

Authors:  J H Toogood
Journal:  CMAJ       Date:  1987-05-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.